In a deal that could earn the Cambridge, Mass.-based pharmaceutical company over $1.03 billion, Merrimack Pharmaceuticals (NSDQ:MACK) said yesterday that it is selling its liposome injection cancer drugs, Onivyde and generic Doxil, to Ipsen (EPA:IPN). Merrimack is also slashing its employee headcount down to just 80 people, after laying off 22% of its 400 employees last October. As a part of the restructuring, the company will focus on its non-small cell lung cancer drug MM-121, metastatic pancreatic cancer program MM-141 and its antibody-directed nanotherapeutic MM310.
According to the deal, Merrimack will receive $575 million in cash as upfront payment and up to $450 million in additional milestone payments based on regulatory approvals. The pharmaceutical company could also earn up to $33 million in payments from its exclusive licensing agreement with Shire for the development and commercialization of Onivyde.
Get the full story at our sister site, Drug Delivery Business News.
The post Merrimack sells liposome injections to Ipsen for $575m appeared first on MassDevice.